Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis - PubMed (original) (raw)
. 1989 Mar 15;43(3):403-9.
doi: 10.1002/ijc.2910430310.
Affiliations
- PMID: 2466800
- DOI: 10.1002/ijc.2910430310
Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis
T C Hsu et al. Int J Cancer. 1989.
Abstract
Responses to the genotoxic effect of bleomycin in lymphocytes of blood cultures, expressed as the average number of chromatid breaks per cell (b/c), varied from less than 0.20 to more than 2.00 in 335 normal individuals. More than 11% of the subjects tested showed a b/c rate above 1.00 and more than 22% showed a b/c rate above 0.80. These individuals are considered sensitive to this radiomimetic drug. The distributional profile of bleomycin responses of the control individuals appears to be representative of the normal human population. In patients with cancers of the colon (83), upper aerodigestive tract (head/neck) (77), and lung (71), the frequencies of subjects in the hypersensitive class were found to be between 40 and 50%, and the response profiles were distinctly different from those of the control population. On the other hand, in a group of elderly cigarette smokers, who exhibited no symptoms of lung cancer, the bleomycin sensitivity profile was significantly skewed toward the more resistant stratum, with only one hypersensitive case among 56 individuals tested (1.78%). The sensitivity profile of patients with breast cancer (82) was similar to that of the control population. Our data suggest that: (1) mutagen sensitivity may play an important role in carcinogenesis of organs and tissues that have direct contact with the external environment (respiratory, digestive, and integumentary systems); (2) it appears to have no significant influence on carcinogenesis of tissues that are not directly exposed to the environment (e.g., breast, brain); and (3) it also has little impact on carcinogenesis in individuals with a hereditary predisposition to cancer (e.g., retinoblastoma, Gardner's syndrome). Development of more effective and precise test systems for carcinogen sensitivity is highly desirable for identification of persons at risk.
Similar articles
- Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract.
Wu X, Gu J, Hong WK, Lee JJ, Amos CI, Jiang H, Winn RJ, Fu KK, Cooper J, Spitz MR. Wu X, et al. J Natl Cancer Inst. 1998 Sep 16;90(18):1393-9. doi: 10.1093/jnci/90.18.1393. J Natl Cancer Inst. 1998. PMID: 9747870 - Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions.
Wu X, Lippman SM, Lee JJ, Zhu Y, Wei QV, Thomas M, Hong WK, Spitz MR. Wu X, et al. Cancer Res. 2002 May 15;62(10):2813-8. Cancer Res. 2002. PMID: 12019158 - Differential mutagen sensitivity of peripheral blood lymphocytes from smokers and nonsmokers: effect of human cytomegalovirus infection.
Albrecht T, Deng CZ, Abdel-Rahman SZ, Fons M, Cinciripini P, El-Zein RA. Albrecht T, et al. Environ Mol Mutagen. 2004;43(3):169-78. doi: 10.1002/em.20012. Environ Mol Mutagen. 2004. PMID: 15065204 - [Genome instability and bleomycin sensitivity test].
Milić M. Milić M. Arh Hig Rada Toksikol. 2010 Jun;61(2):257-66. doi: 10.2478/10004-1254-61-2010-2003. Arh Hig Rada Toksikol. 2010. PMID: 20587401 Review. Croatian. - Mutagen sensitivity: a biological marker of cancer susceptibility.
Hsu TC, Spitz MR, Schantz SP. Hsu TC, et al. Cancer Epidemiol Biomarkers Prev. 1991 Nov-Dec;1(1):83-9. Cancer Epidemiol Biomarkers Prev. 1991. PMID: 1726967 Review.
Cited by
- Cytogenetic characterization of 20 lymphoblastoid lines derived from human individuals differing in bleomycin sensitivity.
Hsu TC, Shillitoe EJ, Cherry LM, Lin Q, Schantz SP, Furlong C. Hsu TC, et al. In Vitro Cell Dev Biol. 1990 Jan;26(1):80-4. doi: 10.1007/BF02624159. In Vitro Cell Dev Biol. 1990. PMID: 1689712 - Case of Patient with AML with Complex Karyotype including Ultra-Rare t(4;8)(q32;q13), t(4;11)(q21;p15) and Familial Aggregation of Myeloid Malignancies.
Milczarek S, Studniak E, Baumert B, Janowski M, Bonda W, Pietrzak J, Łanocha A, Paczkowska E, Zdziarska B, Machaliński B. Milczarek S, et al. Medicina (Kaunas). 2022 Jan 10;58(1):105. doi: 10.3390/medicina58010105. Medicina (Kaunas). 2022. PMID: 35056413 Free PMC article. - Application of mutagen sensitivity assay in a glioma case-control study.
Erdal S, McCarthy BJ, Gurule N, Berwick M, Gonzales E, Byrd J, Flores K, Shimek J, Il'yasova D, Ali-Osman F, Bigner DD, Davis FG, Leyba AN, White KAM. Erdal S, et al. Toxicol Rep. 2018 Jan 9;5:183-188. doi: 10.1016/j.toxrep.2017.12.010. eCollection 2018. Toxicol Rep. 2018. PMID: 29854587 Free PMC article. - Using biomarkers of genetic susceptibility to enhance the study of cancer etiology.
Rothman N, Hayes RB. Rothman N, et al. Environ Health Perspect. 1995 Nov;103 Suppl 8(Suppl 8):291-5. doi: 10.1289/ehp.95103s8291. Environ Health Perspect. 1995. PMID: 8741801 Free PMC article. Review. - [Methylnitrosourea as challenge mutagen in assessment of the DNA mismatch repair (MMR) activity: association with some types of cancer].
Tronov VA, Loginova MIu, Kramarenko II. Tronov VA, et al. Genetika. 2008 May;44(5):686-92. doi: 10.1134/s1022795408050128. Genetika. 2008. PMID: 18672802 Russian.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases